Donepezil in the Treatment of ADHD-Like Symptoms in Youths With Pervasive Developmental Disorder: A Case Series
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Recent studies reported ADHD-like symptoms and cognitive deficits in pervasive developmental disorder (PDD). Because work in dementia documents improvement in executive function deficits with the acetylcholinesterase inhibitor donepezil, the authors reason that similar benefits could be obtained in PDD. Method: The authors describe eight cases of PDD youth ages 10 to 17 treated with donepezil targeting ADHD-like symptoms associated with PDD. Results: Most participants improve ADHD-like symptomatology. In addition, improvement in communication and socialization is noted. Conclusion: Donepezil may have a role in treating ADHD-like symptoms in children with PDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 1×
“Neuroleptics have been used for behavioral dyscontrol and mood stabilization in individuals with PDD (McCracken et al., 2002).”
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Self-citationNicotine effects on adults with attention-deficit/hyperactivity disorder
Levin, E. D., Conners, C. K., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., Rose, J. E., & March, J. (1996) · Psychopharmacology · doi:10.1007/bf02246281 · Cited by 415
Spencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402 · cited 1×
“The degree of improvement was somewhat less than that reported in trials of stimulant and nonstimulant medication (Spencer et al., 1995; Spencer et al., 1996).”
ResultSelf-citationThe Contribution of Neuropathologic Studies to the Understanding of Autism
Kemper, T. L., & Bauman, M. L. (1993) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30176-2 · Cited by 373 · cited 1×
“These clinical observations are supported by other evidence for a role of cholinergic activity in ADHD (Levin, 1992; Wilens et al., 2000) and autism (Bauman & Kemper, 1994; Hardan & Handen, 2002; Kemper & Bauman, 1993; Perry et al., 2001).”
BackgroundWilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1931 · Cited by 230
Self-citationBalducci, C., Nurra, M., Pietropoli, A., Samanin, R., & Carli, M. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1385-7 · Cited by 42
Cited by
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 256
Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment
Reiersen, A. M., & Todd, R. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.657 · Cited by 189
“…symptoms in high functioning ASD n = 16 Mean age: 7.7 years Range: 6–14 years 7 with autism, 7 with Asperger’s, 2 with PDD-NOS Atomoxetine, mean dose 1.2 mg/kg/day Doyle et al. (2006) Series of case reports (from retrospective chart review) in children with ASD plus ADHD symptoms n = 8 10–17…”
BackgroundInfluentialAttention-deficit/hyperactivity disorder in the context of autism spectrum disorders
Murray, M. J. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0145-3 · Cited by 185
Rossignol, D. A., & Frye, R. E. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00087 · Cited by 79
Ivanchak, N., Fletcher, K., & Jicha, G. A. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0305-8 · Cited by 54
“Early case reports described improvements in attention and socialization [84, 88], however controlled clinical trials have failed to show overt efficacy, although a suggestion of a select group of “responders” (22 % of treated subjects) and a potential reduction in motor tics were noted in these studies [84, 88].”
BackgroundResult
Metadata
- Authors
- Doyle, R. L., Frazier, J., Spencer, T. J., Geller, D., Biederman, J., & Wilens, T.
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2006-02
- Volume
- 9
- Issue
- 3
- Pages
- 543-549
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2112123696
- Cited by
- 33
- References
- 7
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.